---
title: A Trial to Evaluate the Correlation Between Spontaneous Catch-up Growth, Clinical Response to Saizen (Recombinant Human Growth Hormone, r-hGH) and Gene Expression Profiling in Children Small for Gestational Age (SGA)
nct_id: NCT01067352
overall_status: TERMINATED
phase: PHASE3
sponsor: Merck KGaA, Darmstadt, Germany
study_type: INTERVENTIONAL
primary_condition: Infant, Small for Gestational Age
countries: Italy
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01067352.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01067352"
ct_last_update_post_date: 2013-12-27
last_seen_at: "2026-05-12T07:29:35.384Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Trial to Evaluate the Correlation Between Spontaneous Catch-up Growth, Clinical Response to Saizen (Recombinant Human Growth Hormone, r-hGH) and Gene Expression Profiling in Children Small for Gestational Age (SGA)

**Official Title:** An Open, Multicenter, Randomized, Controlled Trial to Evaluate the Correlation Between Spontaneous Catch-up Growth, Clinical Response to Saizen (Recombinant Human Growth Hormone, r-hGH) and Gene Expression Profiling in Children Small for Gestational Age (SGA)

**NCT ID:** [NCT01067352](https://clinicaltrials.gov/study/NCT01067352)

## Key Facts

- **Status:** TERMINATED
- **Why Stopped:** This study was discontinued prematurely due to difficulty in participant recruitment.
- **Phase:** PHASE3
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 25
- **Lead Sponsor:** Merck KGaA, Darmstadt, Germany
- **Collaborators:** Merck Serono S.P.A., Italy
- **Conditions:** Infant, Small for Gestational Age
- **Start Date:** 2004-02
- **Completion Date:** 2009-07
- **CT.gov Last Update:** 2013-12-27

## Brief Summary

This open, multicentric, randomized, controlled study is planned to evaluate the correlation between gene expression, spontaneous catch-up growth and therapeutic response to Saizen in SGA children.

## Detailed Description

This open, multicentric, randomized, controlled study was planned to identify genes activated by hGH in SGA children responders to treatment (making it possible in the near future to better identify SGA children likely to benefit from hGH treatment). Furthermore, the study would hopefully allow to verify which genes were responsible of spontaneous catch-up growth in children with diagnosis of SGA at birth but above the third percentile for height at the age of 24 months, and if these genes were the same activated by hGH during the treatment in participants responders. Sixty children born at term (i.e. after the 37th completed week of gestation) and with a diagnosis of SGA (defined as a length less than tenth percentile according to the Italian reference table published by Bertini and Fabris) were planned to be enrolled in the study. Forty participants (group A) were still less than third percentile for height (according to the Tanner reference table) at the age of 24 months, the remaining 20 (group B) being more than or equal to third percentile (thus showing a spontaneous catch-up growth). Group A was randomized to receive Saizen at the daily dose of 0.067 mg/kg (Group A1) or no treatment (Group A2) for two years. All participants were to undergo full clinical examination and blood chemistry at baseline visit and visit after 1,6,12,18 and 24 months for a period of two years. Gene expression analysis using the Clontech Atlas Human Array was performed in all participants at baseline and after one year in order to identify the possible correlation between catch-up growth (either spontaneous or drug-induced) and expression of some genes.

OBJECTIVES

Primary objective:

* To evaluate the correlation between gene expression profiling and catch-up growth (either spontaneous or drug induced after one year of treatment) in SGA children.

Secondary Objectives:

* To evaluate the percentage of participants not treated who show a spontaneous catch-up growth during the two years of observation.
* To assess the safety and tolerability of early treatment with Saizen

## Eligibility

- **Minimum age:** 4 Years
- **Maximum age:** 6 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* SGA at birth (defined as a length at birth equal or below the tenth percentile according to the Italian reference table of Bertini and Fabris)
* Age of 24 Months
* Caucasic
* Born at term (i.e. after the 37th completed week of gestation)
* Height equal or below (Group A) or up (Group B) the third percentile at the age of 24 months according to the Tanner reference table
* Sufficient GH secretion (more than 10 nanogram (ng)/milliliter (ml)) at least to one of the tests commonly used at that age (glucagon, Levo-dopa, arginine, clonidine, Growth Hormone Releasing Hormone (GHRH), GH integrated secretion)
* Normal level of Thyroid-stimulating hormone (THS), Free Triiodothyronine (FT3), Free Thyroxine (FT4), Insulin-like growth factor 1(IGF-1), insulin and haemoglobin A1c (HbA1c)
* Normal level of Immunoglobulin A (IgA)
* Children parents willing to comply with the protocol for the whole duration of the study
* A written Informed Consent before the baseline visit must be obtained from the parent(s) / legal guardian(s)

Exclusion Criteria:

* Congenital malformations (including Silver-Russel syndrome)
* Known abnormal karyotype, especially in girls
* Twins
* Severe psychomotor retardation
* Previous or ongoing treatment with anabolic steroids or r-hGH
* Treatments interfering with the immune system (including bacterial lysate)
* Severe chronic illnesses
* Autoimmune diseases
```

## Arms

- **Group A (A1)** (EXPERIMENTAL) — Participants were allocated to Group A if were still third percentile for height (according to the Tanner reference table) at the age of 4-6 years. Group A would be then randomized to receive Saizen at the daily dose of 0.035 milligram (mg)/kilogram (kg) (Group A1) or no treatment (Group A2) for two years.
- **Group A (A2)** (NO_INTERVENTION) — Participants were allocated to Group A if were still third percentile for height (according to the Tanner reference table) at the age of 4-6 years. Group A would be then randomized to receive no treatment (Group A2) for two years.
- **Group B** (NO_INTERVENTION) — Participants were allocated to Group B being third percentile (thus showing a spontaneous catch-up growth).

## Interventions

- **Recombinant human growth hormone (r-hGH)** (DRUG) — Recombinant human GH were administered subcutaneously (s.c) at the daily dose of 0.067 mg/kg of body weight to Group A1.

## Primary Outcomes

- **Correlation Between Gene Expression Profiling and Catch-up Growth in Small for Gestational Age (SGA) Children** _(time frame: Baseline and Week 48)_ — Gene expression profiling:analysis of ribonucleic acid (RNA) extracted from body tissue or fluids using Clontech Atlas Human Array to study level of activation of genes in tissue analyzed. Analysis was performed to identify possible correlation between catch-up growth (either spontaneous or drug-induced after Week 48) and therapeutic response to rhGH. Spontaneous catch up growth:shown by SGA participants having length more than third percentile at Week 96 without any treatment;drug induced growth was by SGA participants having length more than third percentile at Week 96 with drug treatment.

## Secondary Outcomes

- **Percentage of Untreated Participants Who Showed a Spontaneous Catch-up Growth** _(time frame: Baseline through Week 96)_
- **Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs Leading to Study Drug Discontinuation** _(time frame: Baseline through Week 96)_

## Locations (1)

- Merck Serono S.p.A., Roma, Italy

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.merck serono s.p.a.|roma||italy` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01067352.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01067352*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*